Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) released its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36, Zacks reports. The company had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.
Entrada Therapeutics Stock Down 1.4%
Shares of TRDA traded down $0.12 during midday trading on Thursday, reaching $7.86. 15,234 shares of the stock were exchanged, compared to its average volume of 128,470. The company has a market cap of $298.12 million, a P/E ratio of 4.90 and a beta of 0.04. The stock's 50 day simple moving average is $9.04 and its 200 day simple moving average is $13.58. Entrada Therapeutics has a twelve month low of $7.10 and a twelve month high of $21.79.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Monday, March 31st.
View Our Latest Stock Analysis on Entrada Therapeutics
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Stories
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
